TEPOTINIB
Background and Date of Approval
Tepotinib is a medication containing tepotinib as its active ingredient. It works by slowing or stopping the growth of cancer cells and preventing their spread in the body, particularly in patients with non-small cell lung cancer (NSCLC) harbouring a mutation in the MET gene (found on the surface of certain cancer cells). The United States Food and Drug Administration (FDA) approved tepotinib on February 3, 2021, for treating adult patients with metastatic non-small cell lung cancer (NSCLC) that carries a specific genetic mutation called MET exon 14 skipping. Patients with an allergy to tepotinib or any of its components should not use this medication.
Uses
Tepotinib is used to treat non-small cell lung cancer (NSCLC).
How is it administered?
Take tepotinib exactly as prescribed by your doctor. The recommended dose and dosing schedule may vary depending on your medical condition, age, weight, and other factors. It should be taken with food. Swallow the tablet as a whole with a glass of water. Patients should not chew, crush, or break the tablet, as this may affect the effectiveness of the medication. Avoid doubling the dose to compensate for the missed dose.
Side Effects
Tepotinib is generally well-tolerated, but it can cause side effects like all medications. The most common side effects include peripheral edema (arm or leg swelling), nausea, diarrhea, fatigue, musculoskeletal pain, and dyspnea (shortness of breath). More serious side effects may include interstitial lung disease, and hepatotoxicity (liver damage).
Warnings
Patients should be aware of some warnings associated with tepotinib use. These warnings include the risk of interstitial lung disease, hepatotoxicity, and hypertension, as well as the potential for severe skin reactions, immune-mediated adverse reactions, cataracts, and renal impairment.
Precautions
Individuals with a history of severe allergic reactions to any tepotinib component should not receive it. Inform your healthcare provider of any pre-existing medical conditions, medications, or supplements you are taking before starting treatment with tepotinib. If you experience any new or worsening symptoms during treatment, such as difficulty breathing, yellowing of the skin or eyes, or vision changes, notify your healthcare provider immediately.
Word of Advice
If you have been prescribed tepotinib, adhere strictly to your doctor's instructions. Contact your doctor immediately if you experience unusual symptoms or side effects, including fever, persistent cough, difficulty breathing, abdominal pain, or signs of liver dysfunction. Do not discontinue tepotinib without consulting your doctor first, as doing so may compromise medication effectiveness and treatment outcomes. Pregnant women and those who are breastfeeding should seek advice from a healthcare provider before taking tepotinib. Minimise close contact with individuals who have infections, as this medication suppresses immune function. Maintain a nutritious, balanced diet to support overall health and wellbeing.
References
Merck Limited, Electronic Medicines Compendium (EMC), [Revised on 25 May 2022] [Accessed on 10th May 2023], https://www.medicines.org.uk/emc/product/12970/smpc EMD Serono, Inc., US Food & Drug Administration, [Revised on 3rd Feb 2021] [Accessed on 10th May 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214096s000lbl.pdf Goodman & Gilman's the pharmacological basis of Therapeutics, 13th Edition., 2018, 1549-1674
Frequently Asked Questions
Can tepotinib cause high blood pressure?
Yes, tepotinib can cause or worsen pre-existing hypertension. Patients receiving this medicine should monitor their blood pressure regularly during treatment, and antihypertensive medications may be necessary to control hypertension.
What are the potential skin reactions associated with tepotinib?
Tepotinib can cause severe skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Patients should be monitored for skin rash, blistering, or peeling, and treatment should be discontinued if severe skin reactions occur.
Can tepotinib affect renal function?
Yes, tepotinib may cause renal impairment, and patients with pre-existing renal impairment may be at an increased risk of developing renal toxicity. Patients should have their renal function monitored regularly during treatment.
Is there a risk of cataracts with the use of tepotinib?
Yes, there is a potential risk of developing cataracts with tepotinib. Patients receiving it should have their vision checked regularly during treatment, and treatment should be discontinued if cataracts develop.
Can tepotinib affect fertility?
There is currently no information on whether tepotinib affects fertility in humans. However, animal studies have shown that this medication may cause reversible testicular toxicity in male rats. Patients planning to have children or experiencing fertility problems should discuss their concerns with their healthcare provider before starting treatment.